Mohammad Aghaei, Ardavan
Weleff, Jeremy
Martins, Bradford
Ing, Kevin
Fontenele, Rodrigo
Barnett, Brian S.
Anand, Akhil
Bassir Nia, Anahita
Funding for this research was provided by:
National Institutes of Health (R25MH071584-14, K12 DA000167)
Article History
Accepted: 8 April 2024
First Online: 25 April 2024
Compliance with Ethical Standards
: The Section Editors for the topical collection Psychedelics are Gustavo Angarita and Anahita Bassir Nia. Please note that Section Editor Anahita Bassir Nia was not involved in the editorial process of this article as she is a co-author.
: Dr. Barnett holds stock options in CB Therapeutics. He also serves on advisory boards for CB Therapeutics and Compass Pathways. He receives monetary compensation from DynaMed Plus (EBSCO Industries, Inc.) for editorial work and from Janssen Pharmaceuticals for consulting services. Dr. Barnett has received research funding from MindMed. Dr. Bassir Nia is a member of the Scientific Advisory Board of Synendos Therapeutics AG, Switzerland.
: No animal or human subjects by the authors were used in this study.